Very Low-Dose Sublingual Ketamine for Borderline Personality Disorder and Treatment-Resistant Depression.
Cureus April 1, 2024 Mitchell B. Liester, Rachel Wilkenson, Barry Patterson et al. 3 citations
Borderline personality disorder (BPD) and treatment-resistant depression (TRD) are common mental disorders that are challenging to treat. Ketamine is an N-methyl-D-aspartate receptor antagonist that has shown promise as a rapid-acting antidepressant when administered intravenously. BPD symptoms have also been demonstrated to improve with repeated intravenous administration of ketamine, and a...
DOI: 10.7759/cureus.57654 (opens in new tab)
Full text (opens in new tab)
Ampa receptor
Brain-derived neurotrophic factor
Glutamate dysregulation
Low dose ketamine
+6